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By disease: ischemic heart disease, 1.9 times or 10 days longer; hypertension 1.3 times 
or 4 days longer; congestive heart failure, 1.2 times or 3 days longer; and rheumatoid 
arthritis, 1.4 times or 2 days longer. Obese patients with diabetes and s/p cerebral 
vascular accident had a shorter LOS (0.8 times or 3 days, and 0.8 times or 4 days 
respectively). CONCLUSIONS: Obesity increases the LOS for all-cause hospital admis-
sions among patients with various underlying chronic diseases. This may be due to 
insufficient diagnosis by the primary provider or specialist, inadequate medication 
dosing (eg, pain management), or inadequate support during an inpatient stay. A 
proactive health care policy is needed to guide the management of patients with 
chronic disease who are also obese, with the potential for cost-savings of interven-
tional, pharmaceutical, or surgical treatment of obesity at baseline.
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OBJECTIVES: The aim of the present analysis was to identify the level of the availabil-
ity and total expenditure of medicines for rare diseases with European authorization 
and orphan designation. In Poland all innovative medical technologies and services 
claiming public money founding have to be assessed by Agency for Health Technology 
Assessment (AOTM). Pharmacoeconomic evaluations of new therapies are required 
for all reimbursement decisions and orphan drug manufacturers cannot be exempted 
from providing a full pharmacoeconomic or HTA reports. The criteria of assessment 
connected with clinical and cost effectiveness (threshold is 3xGDP for ICUR/QALY) 
are the same for all kind of drugs. METHODS: All orphan designation admitted by 
European Medicines Agency (EMA) until the end of 2014 were reviewed and analyzed 
from the official website of EMA. Among 792 EMA’s orphan registrations studied 78 
(9,8%) applied to orphan drugs. We compared the outcomes with reimbursement list 
officially published by Ministry of Health. Then it was checked what was the share of 
orphan drugs in overall reimbursement spending. RESULTS: At the end of 2014 there 
were 28 orphan drugs available on the reimbursement list (36% of designed by EMA). 
The total public payer reimbursement spending was € 2.41bn in 2012 and € 2.26bn in 
2013. Orphan drugs have only accounted for a small percentage of the overall drug 
budget in polish health care system (1,5% in 2012 and 3,2% in 2013). CONCLUSIONS: 
In the literature we can find opinions that the relatively low budget impact of orphan 
drugs is often used as an argument in reimbursement decisions. In Poland reimburse-
ment was awarded to the minority of orphan drugs designed by EMA. Very strict 
requirements in order to ensure compatibility with law directives could potentially 
influence negative reimbursement decisions for orphan drugs.
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BACKGROUND: Obesity is a pathology that leads to several co-morbidities such as 
diabetes and hypertension. In Brazil obesity rates (BMI > 30kg/m2) raised from 11.8% 
in 2006 to 17.5% in 2013. Bariatric Surgery is the most effective treatment to achieve 
excess weight lost for morbid patients. It is estimated that Brazil has around 1.8 
million people with BMI > 40kg/m2, considering that Brazil has an universal health 
care system and 25% of the population relies in the private health care sector, sev-
eral people are eligible to get bariatric surgery OBJECTIVES: Evaluate the use of the 
resources dedicated to treat morbid obese patients in the Brazilian public health 
care system (SUS) from 2008 to 2013 METHODS: Revised data of expenditures, num-
ber of surgeries and length of stay related to bariatric surgery in the database of the 
IT Department of SUS (DATASUS) RESULTS: The number of certified hospitals that 
perform bariatric surgery increased by 35% and the percentage of states covered 
by certified hospitals rose from 60% to 74%. During the same period the number of 
procedures increased by 113%. Despite the increase in the number of procedures 
by 113%, the days of hospitalization required for surgeries increased only 52%; this 
is due the average length of stay reduction from 5.7 days to 4.1 days, showing a 
better efficiency among hospitals. The total expenditure in bariatric surgeries rose 
by 161%. CONCLUSIONS: Analysis demonstrated that the access to the bariatric 
procedure in Brazil has increased in the past five years. The hospitals’ efficiency 
improved during the same period, decreasing the average length of stay. Today 
the Brazilian public health care system provides surgery to less than 0.75% of the 
eligible population and despite the access increase; more resources (physicals and 
infrastructure) are needed in order to treat the morbid obese population
PSY74
canadian reTroSPecTive claiMS daTa analYSiS of biologicS 
SwiTching and reTenTion PaTTernS in PSoriaSiS PaTienTS
Millson B.1, Poulin-Costello M.2, Garces K.2
1IMS Brogan, Kirkland, QC, Canada, 2Amgen Canada Inc., Mississauga, ON, Canada
OBJECTIVES: To describe treatment patterns and cost in patients with PSO (psoria-
sis) receiving biologic therapies (BT). METHODS: A retrospective cohort of medica-
tion claims data from IMS Brogan Private (Canadian national) and Public (Ontario 
and Quebec) Drug Plan databases was analysed. Biologic-naïve PSO patients > 18 
years of age were selected between 01/01/2007 and 03/30/2011 and followed for 
24 months to understand lines of therapy, retention on BT, and annual therapy 
costs. Target biologics included adalimumab, etanercept, infliximab and usteki-
numab. RESULTS: 3,546 patients were identified. Of those, 44% initiated etanercept, 
26% adalimumab, 19% ustekinumab, and 10% infliximab. 32% of patients remained 
on 1st line therapy, 16% switched, and 52% stopped therapy over the 24 month 
period. Median days on 1st line therapy was longer in public than private plans (502 
vs. 357). Of those who switched, 556 received 2 lines, and 105 received 3 or more lines 
of BT. In a retention model of private plan patients, those who supplemented with 
non-biologic PSO therapies were 16% - 42% more likely to stay on BT than those tak-
the induction period for each drug. Overall, 63% of patients experienced a dose 
escalation, of which 68% occurred within the first year, excluding induction. Peak 
frequency of dose escalation occurred between weeks 11-30. Calculated daily, esca-
lated dose was greater than maintenance by 9% for adalimumab, 14% for etanercept, 
and 28% for ustekinumab. CONCLUSIONS: Across all treatments, dose escalation 
was recorded in over 60% of patients, most often in the first year of treatment, 
indicating that patients may require additional doses to maintain response. These 
data highlight the need for new treatments which provide high sustained efficacy, 
with a rapid onset of action.
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OBJECTIVES: To quantify the effect of the implementation of Florida’s PMP and 
pill mill laws on overall and high risk opioid prescribing, utilization, and dispens-
ing. METHODS: We applied comparative interrupted time series analyses to IMS 
Health LRx LifeLink data to characterize the effect of PMP and pill mill law imple-
mentation on a closed cohort of patients, prescribers and retail pharmacies between 
July 2010 and Sept 2012 in Florida (intervention state) compared with Georgia (con-
trol state). We conducted numerous sensitivity analyses including varying the 
length of observation and modifying requirements for continuous observation of 
individuals throughout the study period. RESULTS: From July 2010 to September 
2012, a cohort of 2.6 million patients, 431,890 prescribers and 2,829 pharmacies was 
associated with approximately 480 million prescriptions in Florida and Georgia, 
8% of which were for opioids. Average total monthly opioid volume (355.1 vs. 124.2 
kilograms [kg]), average dose per transaction (55.2 vs. 46.6 milligrams [mg] MEDD), 
and average number of days supply (18.4 vs. 16.0 days) were each higher in Florida 
than Georgia prior to implementation of Florida’s PMP and pill mill laws. Overall, 
Florida’s laws were associated with statistically significant declines in opioid volume 
(3.7 kilograms/month) and MEDD (0.46 mg/month), without any change in days 
supply. Reductions were limited to prescribers and patients with the highest base-
line opioid prescribing and utilization, respectively. Sensitivity analyses varying the 
time windows and enrollment criteria supported the main results. CONCLUSIONS: 
Implementation of PMP and pill mill laws in Florida was associated with decreases 
in prescription opioid dispensing relative to Georgia among patients and providers 
with high levels of opioid utilization at baseline.
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OBJECTIVES: Hemophilia is an inherited condition requiring lifelong, expensive 
treatment. Initiating prophylaxis treatment with factors VIII (hemophilia A) or 
IX (hemophilia B) at an early age has been shown to be effective in improving 
health outcomes. In 2007 the medical advisory council of the National Hemophilia 
Foundation (NHF’s MASAC) recommended prophylaxis treatment as the optimal 
therapy for these patients. The study objectives were:(1) To explore the economic 
burden over the patient’s lifespan; (2) To quantify changes in factor VIII/IX utilization 
and related costs over the past decade. METHODS: A retrospective, US health insur-
ance claim database (2004-2012) analysis was conducted. Males with ≥ 2 pharmacy 
claims for a hemophilia drug within 3 months, and continuous enrollment for ≥ 180 
days were included. Patients utilizing inhibitor treatments were excluded. Annual 
payer and patient out-of-pocket (OOP) expenses were calculated by service category 
(inpatient, outpatient, medications), and stratified by patient’s age and calendar 
year. Costs were adjusted to 2013USD. Annual supply days (ASD) per patient were 
calculated; ASDs over time were compared using a t-test. RESULTS: For hemophilia 
A (N= 727), increase in payers’ costs was observed during the first 4 decades of life, 
peaking at age 34 ($273,669) decreasing thereafter, and annual OOP staying constant 
at $2,589/year. For hemophilia B (N= 161), an increase in payers’ costs was observed 
during the first 3 decades of life peaking at age 29 ($281,981) decreasing thereafter 
with annual OOP at $2,401/year. Between 2007 and 2012, ASD per patient increased 
significantly for both factor VIII (ADVATE®: 160.5 vs. 249.9 days, p= 0.00029) and 
factor IX (BENEFIX®: 132.8 vs. 214.7 days, p= 0.0255) coinciding with payers’ drugs 
cost over the same time period. (Hemophilia A: $186,283 to $212,747respectively; 
hemophilia B: $147,778 to $186,851 respectively). CONCLUSIONS: Over the past dec-
ade, the mean per patient consumption of factor replacement therapy has increased 
substantially, in line with new treatment guidelines.
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OBJECTIVES: An obese body mass index (BMI) increases morbidities, however there 
are few chronic disease registries that can quantify the cost of obesity. Clalit Health 
Services (CHS), with complete longitudinal data of over 4 million members, provides 
an ideal format for comparing health care utilization between obese and non-obese 
patients to inform the need for improved health care policy. METHODS: For the years 
2011-2013 inclusive, we took two random samples of 10,000 obese (BMI> 30) patients 
and 10,000 normal and underweight (BMI< = 25) from the CHS database both accord-
ing to Clalit population age standard. We then extracted their additional chronic 
diseases from the CHS registry. Finally, we compared the average length of stay (LOS) 
for inpatient admissions between the groups, by disease. RESULTS: Obese patients 
with underlying chronic disease had, on average, a 27% increased LOS compared to 
non-obese patients with chronic disease. The greatest effect was seen among obese 
patients with chronic renal failure, whose LOS was 2.7 times or nearly 20 days longer. 
